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Background: In order to identify miRNAs expression profiling from genome-wide screen for diagnosis of acute
myocardial infarction (AMI) and angina pectoris (AP), we investigated the altered profile of serum microRNAs in
AMI and AP patients at a relative early stage.
Methods: Serum samples were taken from 117 AMI patients, 182 AP patients and 100 age-and gender-matched
controls. An initial screening of miRNAs expression was performed by Solexa sequencing. Differential expression
was validated using RT-qPCR in individuals samples, the samples were arranged in a two-phase selection and
validation.
Results: The Solexa sequencing results demonstrated marked upregulation of serum miRNAs in AMI patients
compared with controls. RT-qPCR analysis identified a profile of six serum miRNAs (miR-1, miR-134, miR-186,
miR-208, miR-223 and miR-499) as AMI biomarkers. MiR-208 and miR-499 were elevated higher in AP cases than in
AMI cases. The ROC curves indicated a panel of six miRNAs has a great potential to offer sensitive and specific
diagnostic tests for AMI. More especially, the panel of six miRNAs presents significantly differences between the
AMI and AP cases.
Conclusions: The six-miRNAs signature identified from genome-wide serum miRNA expression profiling may serves
as a fingerprint for AMI and AP diagnosis.
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Coronary heart disease (CHD) is a major cause of death
in the world’s population. Acute myocardial infarction
(AMI) is also a leading source of morbidity and hospital-
izations. In US, total CHD prevalence is 7.0% in adults
and the overall prevalence for AMI is 3.1%; 18% of co-
ronary attacks are preceded by longstanding angina
pectoris (AP) [1]. About 3 million people die from CHD
every year and now an estimated 2 million people have
AMI in China. In recent years, the survival of AMI pa-
tients has improved with better therapeutic strategies
such as percutaneous coronary intervention and coro-
nary artery bypass graft [2]. However, the absolute* Correspondence: xiangy@nju.edu.cn; cyzhang@nju.edu.cn
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reproduction in any medium, provided the ornumber of deaths has remained almost constant because
of an increase in the size of the population and the pro-
portion of older people [3]. An early and correct diagno-
sis of AMI is critical to enhance the survival of patients.
Now the prediction of AMI is still an urgent matter of
attention. Currently, cardiac troponin T (cTnT) and cre-
atine kinase MB (CK-MB) are widely used as the most
reliable biomarkers in clinical diagnosis [4]. Elevations in
these biomarkers can reflect myocardial necrosis [5].
However, without clinical evidence of ischaemia, we
should investigate other aetiologies of myocardial necro-
sis, such as myocarditis, aortic dissection, pulmonary
embolism, congestive heart failure, renal failure [6,7]. Be-
sides, the ECG is an integral part in the diagnosis of
suspected AMI [8]. While, ST deviation may be also ob-
served in conditions such as acute pericarditis, LV
hypertrophy, Brugada syndrome, and early repolarizationhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Flow chart of the experimental design.
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brosis. Therefore, it is quite essential to explore novel
biomarkers with more high sensitivity and specificity for
the diagnosis of AMI.
MicroRNAs (miRNAs), endogenous non-coding RNA
molecules of 19 to 24 nucleotides in length, are negative
regulators of gene expression. We have systematically
discovered that miRNAs are stably present in human
serum/plasma and circulating miRNAs can serve as bio-
markers for various diseases. We have investigated the
expression profile of serum miRNA in patients with
non-small cell lung carcinoma, colorectal cancer, and
type 2 diabetes [10-14]. Recently, miRNAs have been
demonstrated to play an important role in AMI. MiR-1,
miR-133a, miR-208, and miR-499-5p are considered
cardio- or skeletal- muscle specific and are candidates as
biomarkers for myocardial infarction [15-20]. However,
the global miRNA pattern in the sera of AMI and AP
patients has not been determined.
In order to identify miRNAs expression profiling from
genome-wide screen for AMI and AP diagnosis, we
compared the levels of miRNAs in plasma of 100 control
individuals, 117 AMI patients and 182 AP patients in
this study. After initial screening by Solexa sequencing,
we validated the results at the individual level by using a
stem-loop RT-qPCR assay.
Methods
Study design, patients and controls
A multiphase, case–control study was designed to identify
serum miRNAs as surrogate markers for AMI (Figure 1).
In the initial biomarker-screening stage, pooled serum
samples from 20 AMI patients and 20 controls underwent
Solexa sequencing (See Additional file 1: Table S1) to
identify miRNAs that showed significant differences be-
tween the AMI cases and matched controls. Subsequently,
we performed a biomarker confirmation analysis with a
hydrolysis probe–based RT-qPCR assay to refine the num-
ber of serum miRNAs in the AMI signature. This analysis
was carried out in 2 phases: (a) the biomarker-selection
phase, in which serum samples from 20 AMI patients and
20 control individuals formed the training set, and (b) the
biomarker-validation phase, in which serum samples from
an additional 97 AMI patients and 80 healthy controls
formed the validation set. Besides, the selected miRNAs
were also examined by RT-qPCR in the serum samples
from 182 AP patients.
Whole blood samples were collected from the Depart-
ment of Cardiology in the First Affiliated Hospital
of Nanjing Medical University between March 2010 and
September 2011. The timing of blood collection for the
miRNAs analysis is within 2h in the emergency room after
hospitalization. The AMI patients were clinically diagnosed
as Universal Definition of Myocardial Infarction [21].The AP patients were clinically diagnosed according to
the Guidelines [22]. All patients were eligible according
to diagnostic symptoms together with electrocardiogram.
Selective coronary arteriography of the right and left cor-
onary arteries was performed on a Digital Cardiovascular
X-ray Imaging System. All samples were collected from
consenting individuals according to protocols approved
by the ethics committee of the First Affiliated Hospital
of Nanjing Medical University. The control individuals
showed normal electrocardiographic findings and no his-
tory of cardiovascular disease. Each participant provided
a written informed consent and ethics permission was
obtained for the use of blood samples.
Serum collection and RNA extraction
Separation of the serum was carried out by centrifuga-
tion at 3 000 g for 10 min, followed by a 15-min high-
speed centrifugation at 12,000 g of blood samples. Then,
the supernatant sera were stored at −80°C.
For the Solexa sequencing assay, we collected two pools
of sera from 20 AMI patients (2 ml each) and 20 healthy
controls (2 ml each) separately. The total RNA of each
pool was extracted by using Trizol LS Reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions.
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purification to eliminate remanent proteins.
For the RT-qPCR assay, we extracted total RNA from 200
μl serum through phenol/chloroform purification. Firstly,
we mixed 200 μl serum with 200 μl diethylpyrocarbonate-
treated water, 200 μl phenol and 200 μl chloroform. Then,
we centrifuged the mixture at 12,000 g for 15 min at 25°C,
collected the upper aqueous layer and added 40 μl sodium
acetate (3mol/L) and 800 μl isopropyl alcohol to it. Subse-
quently, the solution was put at −20°C for 1 hour. After that,
it was centrifuged at 16,000 g for 20 min at 4°C. Then the
RNA was washed once by 1 ml 75% ethanol and dried at
room temperature. At last the RNA pellet was dissolved
in 20 μl diethylpyrocarbonate-treated water and stored
at −80°C.
Solexa sequencing
Firstly, the total RNA was extracted as mentioned above.
Through PAGE purification, total small RNA molecules
under 30 bp were isolated. After ligating a pair of adap-
tors to their 5’ and 3’ ends, the small RNA molecules
were amplified for 17 cycles and then fragments about
90 bp were isolated from agarose gels. The Illumina
Genome Analyzer (Illumina, San Diego, USA) was used
for cluster generation and sequencing analysis according
to the manufacturer’s instructions. Then we processed
the data by computational analysis.
Quantification of miRNAs by RT-QPCR analysis
Briefly, 2 μl of total RNA was reverse-transcribed to cDNA
using AMV reverse transcriptase (TaKaRa, Dalian, China) and
the stem-loop RT primer.Real-time RT-qPCR was performed
using TaqMan miRNA probes (Applied Biosystems, Foster
City, CA, USA) on the Applied Biosystems 7300 Sequence
Detection System (Applied Biosystems). All reactions were
run in triplicate. After reaction, the threshold cycle (Cq) values
were determined using the fixed threshold settings. To cal-
culate the absolute expression levels of the target miRNAs,
a series of synthetic miRNA oligonucleotides (dissolved in
water) of known concentrations (from 1 fM to 105 fM)
were also reverse-transcribed and amplified. The absolute
amount of each miRNA was then calculated by referring
to the standard curve (See Additional file 1: Figure S1).
Since U6 and 5S rRNA are degraded in serum samples and
there is no current consensus on housekeeping miRNAs for
qRT-PCR analysis of serum miRNAs, the expression levels of
miRNAs were directly normalized to serum volume in our
study.
Statistical analysis
Quantitative data are presented as mean ± standard error.
Statistical significance was determined using Student’s t-test.
P<0.05 was considered statistically significant.We constructed the ROC curve and calculated the area
under the ROC curve (AUC) to evaluate the specificity and
sensitivity of AMI and AP prediction. Risk score analysis
was also used by us. The risk score of each miRNA de-
noted as s, was set as 1 if the expression level was greater
than the upper 95% reference interval for the correspond-
ing miRNA level in controls and as 0 if otherwise. A risk
score function (RSF) was defined according to a linear
combination of the expression level for each miRNA. The
RSF for sample i using the information from the six
miRNAs was: RSFi ¼ Σ6j¼1Wj:sij.
In the above equation, sij is the risk score for miRNA j on
sample i , and Wj is the weight of the risk score of miRNA
j. To determine the Ws, six univariate logistic regression
models were fitted using the disease status with each of the
risk scores. The regression coefficient of each risk score
was used as the weight to indicate the contribution of each
miRNA to the RSF. ROC curves were then used to evaluate
the diagnostic effects of the profiling and to find the appro-
priate cutoff point. All the statistical analyses were
performed with Statistical Analysis System software (v.9.1.3;
SAS Institute, Cary, NC).Results
Description and clinical features of the patients
In this study, we included 117 AMI patients, 182 AP pa-
tients and 100 control individuals. Whole blood samples of
patients or healthy donors were collected prior to any thera-
peutic procedure. The patients were clinically and patho-
logically diagnosed with AMI or AP at the First Affiliated
Hospital of Nanjing Medical University; control participants
were also recruited from a large pool of individuals seeking
a routine health checkup at the First Affiliated Hospital of
Nanjing Medical University. As shown in Table 1, there
was no significant difference in the age, gender and ethni-
city between the patients and the controls.Solexa sequencing of serum miRNAs
For the Solexa sequencing assay, we collected two pools of
sera from 20 AMI patients (2 ml each) and 20 healthy con-
trols (2 ml each) separately (See Additional file 2: Solexa
sequencing). The Solexa data showed that miRNAs were
the major components of small RNAs (<30bp) in serum
(See Additional file 1: Table S2). Among the 1223 serum
miRNAs detected by Solexa sequencing, 394 miRNAs were
found in healthy controls and 637 miRNAs were found in
AMI patients (See Additional file 1: Table S3). A miRNA
was considered altered if Solexa sequencing detected 1000
copies in the patient group and the miRNA showed at least
a 5-fold difference between the AMI patients and con-
trols. Based on these criteria, 21 miRNAs showed
significant differences between the AMI cases and
matched controls (See Additional file 1: Table S4).
Table 1 Demographic and clinical characteristics of the patients and control individuals in the training and validation
sets
Characteristics Control AMI AP P1 P2 P3
(n=100) (n=117) (n=182)
sex (F/M) 19/81 20/97 49/133 7.17×10-1 1.97×10-1 7.77×10-2
age 61.10±7.97 62.70±11.40 65.30±9.98 2.69×10-1 4.00×10-4 3.47×10-2
Hypertension 53/100 69/117 127/182 3.40×10-1 4.91×10-3 6.81×10-2
Diabetes 12/100 29/117 44/182 1.50×10-2 1.41×10-2 8.72×10-2
Glucose 5.37±1.47 6.53±2.79 5.51±1.38 4.47×10-4 4.71×10-1 7.19×10-5
EF% 64.38±5.45 59.19±8.38 63.75±6.67 1.03×10-5 4.90×10-1 3.41×10-6
HDL(mmol/L) 1.17±0.30 1.06±0.28 1.12±0.62 1.84×10-2 5.12×10-1 4.80×10-2
LDL(mmol/L) 2.95 ±0.79 2.81±0.86 2.61±0.77 2.77×10-1 8.20×10-4 3.57×10-2
CK-MB(U/L) 15.26±20.91 80.84±121.17 13.06±12.60 2.10×10-4 3.72×10-1 6.80×10-11
cTnT(ng/ml) 0.15±0.27 0.77±0.74 0.14±0.21 2.77×10-8 8.64×10-1 6.66×10-20
EF, Left ventricular ejection fractions; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; CK-MB, Creatine kinase MB; cTnT, Cardiac troponin T. P 1:
comparison between patients with AMI and control. P 2: comparison between patients with AP and control. P 3: comparison between patients with AMI and AP.
AMI, acute myocardial infarction. AP, angina pectoris.
Figure 2 MiRNAs levels in AMI patients and control samples in
the training set. Serum levels of the six miRNAs were measured in
20 AMI and 20 healthy control subjects using a hydrolysis probe-
based RT-qPCR assay. (*P<0.05, **P<0.01, ***P<0.001).
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We used RT-qPCR assay to confirm the expression of
candidate miRNAs. The RT-qPCR assay for measuring
plasma miRNA concentrations was reliable and reprodu-
cible (See Additional file 1: Figure S1). MiR-208 was also
tested by RT-qPCR because it had been shown to be
dysregulated in AMI serum (15). In the training set,
miRNAs were measured in a separate set of individual
serum samples from 20 AMI patients and 20 healthy
controls of the previous step; only miRNAs with a mean
fold change > 2 and a p value < 0.05 were selected for
further analysis. We used these criteria to generate a list
of 6 miRNAs that showed a significant differential ex-
pression between AMI patients and controls. Compared
to their levels in the control samples, these six miRNAs
(miR-1, miR-134, miR-186, miR-208, miR-223 and miR-
499) in the AMI samples were increased to 2.02, 4.93,
3.34, 4.87, 5.09 and 3.39 folds, respectively (Figure 2).
These six miRNAs were then chosen for the next vali-
dation in a larger cohort comprised of 97 AMI patients
and 80 matched controls. The miRNAs expression pattern
alterations in the validation set were consistent with those
in the training set. The levels of the six miRNAs were sig-
nificantly higher in the AMI cases compared to the con-
trol subjects. When compared to their concentrations in
normal controls, the fold changes were 1.55, 2.68, 1.99,
4.09, 1.57 and 1.80, respectively (Figure 3). The differential
expression of the six miRNAs in the 117 AMI samples
compared to the 100 controls is shown in Figure 4A–F.
The selected six miRNAs were also examined by RT-
qPCR in the samples from 182 AP patients. The result
revealed that three miRNAs (miR-186, miR-208 and miR-
499) showed significant difference between the AP patients
and controls (Figure 4C-D,F). All these 6 miRNAs
presented statistically significant differences between AMIand AP cases, about 1.4 to 3.5 fold changes (Figure 4A-F).
Among these 6 miRNAs, miR-208 and miR-499 were ele-
vated higher in AP cases than in AMI cases.
ROC curve analysis
ROC (receiver-operating characteristic) curves are based
on different ways of dichotomous, false-positive rate for
the horizontal coordinate, sensitivity to ordinate draws a
curve. ROC curve and the area under the curve (AUCs,the
area under the curves) can be used as a diagnostic method
for evaluation of the accuracy of the indicators. ROC curves
constructed to compare the relative concentrations of the 6
miRNAs for AMI patients and healthy controls yielded
the following AUCs: miR-1, 0.696 (95% CI, 0.593–
0.799); miR-134, 0.657 (95% CI, 0.551–0.763); miR-186,
0.715 (95% CI, 0.614–0.817); miR-208, 0.778 (95% CI,
0.686–0.869); miR-223, 0.741 (95% CI, 0.645–0.838) and
Figure 3 MiRNAs levels in AMI patients and control subjects in
the validation set. Serum levels of the six miRNAs were measured
in 97 AMI and 80 healthy control subjects using a hydrolysis probe-
based RT-qPCR assay. (*P<0.05, **P<0.01, ***P<0.001).
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Figure S2, Additional file 1: Table S5). Also, we obtained the
AUCs for cTnT and CK-MB and they were 0.800 (95% CI,
0.714–0.887) and 0.683 (95% CI, 0.579–0.786) respectively.
To evaluate the usefulness of the six miRNAs for
detecting AP, we performed ROC curve analyses on the
selected miRNAs and obtained the respective AUCs
(See Additional file 1: Figure S3, Additional file 1: Table S5).
Besides, we also calculated that AUCs ranged from 0.591 to
0.764 for the AMI and AP groups (See Additional file 1:
Figure S4, Additional file 1: Table S5).
Risk score analysis
To further evaluate the diagnostic value of the 6-miRNA
profiling system, we used a risk score formula to calcu-
late the RSF for AMI and control samples. Samples were
ranked according to their RSF and then divided into a
high-risk group representing the predicted AMI cases,
and a low-risk group representing the control individuals
(See Additional file 1: Table S6). The ROC curves were
then used to evaluate the diagnostic effects and to find
the appropriate cutoff point. Figure 5A-C shows that
the AUC for the 6-miRNAs profiling system was 0.811
(95% CI,0.729–0.893). Our results demonstrated that the
combination of six miRNAs has a great potential to offer
more sensitive and specific diagnostic tests.
We also calculated the RSF for AP and control sam-
ples (See Additional file 1: Table S6). Figure 5D-F shows
that the AUC value of the 6-miRNAs profiling system
was 0.953 (95% CI, 0.915-0.992) markedly higher than
those of cTnT (AUC, 0.518; 95% CI, 0.399-0.637) and
CK-MB (AUC, 0.418; 95% CI, 0.299-0.536). Expression
level of the six miRNAs was also analyzed by risk score
for AMI and AP patients. As shown in Figure 5G-I, the
AUC values of the six-serum miRNAs signature (AUC,
0.830; 95% CI, 0.751-0.910) were higher than those ofcTnT (AUC, 0.768; 95% CI, 0.672-0.864) and CK-MB
(AUC, 0.709; 95% CI, 0.606-0.812). The results clearly
indicate that a panel of miRNAs has a great potential for
AP diagnosis.
Discussion
As AMI is among the most frequent causes of illness
and death, an early diagnosis is essential. Although
current studies have revealed a link between the expres-
sion of miRNAs and the development of AMI, these
studies mainly focused on miRNAs expressed in tissues
[17,23,24]. Collecting tissue sample is invasive as it relies
on surgical sections. In contrast, serum sample can be
obtained with easy accessibility and handled with low
cost. Our group has confirmed that miRNAs in human
serum and plasma are quiet stable [11,14]. One possible rea-
son is that serum miRNAs are packaged and secreted into
the blood within the microvesicles, which also named
exosomes or sheding vesicles [14,25-27]. MiRNA-argonaute
complexes are also the stable forms in which miRNAs exist
in blood [28]. In addition, they may be chemically modified,
e.g. methylation [29].
In this study, we performed a high-throughput Solexa
sequence assay as an initial screening stage and used
multiple RT-qPCR assays with individual serum samples
to confirm the serum miRNAs profile. We systematically
determined the expression levels of serum miRNAs in
AMI patients and identified six serum miRNAs (miR-1,
miR-134, miR-186, miR-208, miR-223 and miR-499) sig-
nificantly up-regulated in AMI patients compared to
control subjects. The AUC value based on the six-serum
miRNAs signature was progressively higher than any
single miRNA-based assay in the diagnosis of AMI.
ROC analysis showed that the six-miRNAs profiling sys-
tem will be a potential complementarity of biomarkers
such as cTnT, CK-MB, etc. for the clinical diagnosis of
AMI.
AP is a common presenting symptom among patients
with coronary artery disease, and 6 to 8 percent of pa-
tients with AP have myocardial infarction or die within
the first year after diagnosis [30]. Our study revealed
that miR-186, miR-208 and miR-499 showed significant
differences between AP patients and controls. All the 6
miRNAs presented statistically significant differences be-
tween the AMI and AP; and risk score based on the six-
serum miRNAs signature was progressively higher than
the conventional clinical biomarker cTnT and CK-MB.
Besides, miR-208 and miR-499 were elevated higher in
AP than in AMI cases, which suggests that the two
miRNAs may have a higher sensitivity in diagnosis
of AP. Although the underlying mechanisms remain un-
clear, the packaging of specific miRNA populations into
microvesicles appears to be a selective process. As a new
type of signaling molecule, secreted miRNAs can have
Figure 4 MiRNAs expression in AMI patients, AP patients and control subjects. Serum levels of the six miRNAs were measured in 117 AMI
cases, 182 AP cases and 100 healthy control subjects using a hydrolysis probe-based RT-qPCR assay (A-F). (*P<0.05, **P<0.01, ***P<0.001).
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ered independent of cell contact or adhesion, and can
deliver multiple messages at once and regulate numer-
ous target genes simultaneously, allowing immediate
control over target cells [31,32].
The latest results of our group have proved that
microvesicles derived from cultured THP-1 cells contain
miRNAs and THP-1 cells can selectively package
miRNAs into microvesicles in circulating and cultured
cell medium under various stimuli including LPS, AGEs,
OA/PA and other classic acute or chronic inflammatoryfactors [33]. We will focus on their critical contribution
to pathological processes of coronary heart disease. A
better known of the properties and functions of these
small regulators of gene expression may favour the de-
sign of novel therapeutic approaches for prevention and
treatment of coronary heart disease in the future. Here
in this study, our results showed that detecting the pro-
file of serum miRNAs may distinguish AMI from AP.
Like many other novel biomarkers at their early stages
of research, circulating miRNAs require extensive inves-
tigation to validate their great potential.
Figure 5 ROC curves constructed to compare the relative concentrations of the 6 miRNAs. ROC curves for the 6-miRNAs panel, cTnT and
CK-MB to differentiate AMI cases from the controls(A-C); ROC curves for the 6-miRNAs panel, cTnT and CK-MB (D-F) to differentiate AP cases from
the controls; ROC curves for the 6-miRNAs panel , cTnT and CK-MB (G-I) to differentiate AMI cases from AP cases.
Li et al. BMC Medical Genomics 2013, 6:16 Page 7 of 9
http://www.biomedcentral.com/1755-8794/6/16Of the 6 significantly altered miRNAs in AMI, some
have been reported to be involved in cardiac injury or
protection by altering key signaling elements. It has been
shown that miR-499 is involved in inhibiting apoptosis
and myocardial infarction induced by anoxia and ische-
mia through mechanisms involving p53, calcineurin andDrp1 in executing apoptosis program in the heart [34]. MiR-
1 is preferentially expressed in adult cardiomyocytes and
skeletal muscle, and is known to regulate cardiomyocyte
apoptosis through different mechanisms [35-38]. MiR-208
has also been shown to affect muscle function and perfor-
mance by regulating myosin gene expression [39]. Knockout
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brosis in a murine aortic banding model [40]. All of these
findings support a role for the selected miRNAs in car-
diac function.
Conclusions
Our results suggested that a combination of six serum
miRNAs is more reliable than the single miRNA-based
assay in the diagnosis of AMI. A panel of 6-serum
miRNAs also is a sensitive indicator of AMI and AP at a
relative early stage. Their usefulness in the establishment
of a rapid and accurate diagnosis of AMI remains to be
determined in unselected populations of patients with
acute chest pain.
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